The Lynx Group

Alice Goodman

Authored Items

Bevacizumab Maintenance Improves Survival in mCRC, but Added Erlotinib Is of No Value

September 2013, Vol 2, No 6 - Uncategorized

Bevacizumab maintenance therapy following induction with bevacizumab-based chemotherapy significantly increases progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). However, the addition of erlotinib in the maintenance phase does not increase overall survival (OS) compared with bevacizumab alone. KRAS status was not a predictor of benefit from erlotinib in [ Read More ]

Olaparib Maintenance Therapy Slows Progression in Patients With Ovarian Cancer and BRCA Mutations

September 2013, Vol 2, No 6 - Uncategorized

Olaparib maintenance therapy prolonged progression-free survival (PFS) and the time to disease progression after a second subsequent therapy (PFS2) in patients with platinum-sensitive relapsed serous ovarian cancer (SOC). The effect of olaparib was particularly robust in patients with a BRCA mutation in an updated analysis of Study 19 presented at [ Read More ]

Prostate and Kidney Cancer News From the 2013 Genitourinary Cancers Symposium

April 2013, Vol 2, No 2 - Uncategorized

Approximately 2350 urologists, oncologists, surgeons, radiation oncologists, and other oncology healthcare professionals gathered in Orlando, Florida, to attend the 2013 Genitourinary Cancers Symposium. The symposium, sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology, allows attendees to learn about [ Read More ]

Severe Diarrhea Associated With Molecularly Targeted Agents Can Impact Quality of Life and Healthcare Resource Utilization

September 2012, Vol 1, No 4 - Conference News

A preliminary report of a meta-analysis of clinical trials of molecularly targeted therapies shows that they are not benign and can add to the toxicity of standard chemotherapy. In particular, increased rates of oral mucositis and diarrhea are reported with several FDA-approved agents. Increased mucositis seen with bevacizumab and erlotinib [ Read More ]

Prostate Cancer Roundup

August 2012, Vol 1, No 3 - Uncategorized

Nearly 3000 abstracts were selected for presentation at the recent ASCO 2012 Annual Meeting, many of them related to some aspect of personalized medicine. Below are some highlights selected from the meeting that focus on potential genomic predictors of aggressive versus indolent disease and on potential biomarkers. 6-Gene Model Identifies [ Read More ]

New Targeted Therapies and New Biomarkers Explored at ASCO 2012

August 2012, Vol 1, No 3 - Uncategorized

Below are some highlights of presentations at the 2012 ASCO Annual Meeting related to targeted therapies and personalized (precision) medicine. T-DM1 The anti-body drug conjugate T-DM1 significantly prolonged progression-free survival (PFS) compared with standard capecitabine/lapatinib therapy for treatment of advanced HER2-positive breast cancer in the EMILIA trial (Abstract LBA1). Median [ Read More ]

ALK-Targeted Agent Has High Activity in Some Childhood Cancers

June 2012, Vol 1, No 2 - Conference Correspondent

In a preliminary phase 1 study, the targeted drug crizotinib (Xalkori) stabilized disease progression and, in some children, eradicated cancer cells in relapsed, refractory, aggressive childhood cancers that are likely to harbor genetic abnormalities in the ALK gene: anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and aggressive neuroblastoma. [ Read More ]

Sign me up!